These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 34101078)

  • 21. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.
    Guttery DS; Page K; Hills A; Woodley L; Marchese SD; Rghebi B; Hastings RK; Luo J; Pringle JH; Stebbing J; Coombes RC; Ali S; Shaw JA
    Clin Chem; 2015 Jul; 61(7):974-82. PubMed ID: 25979954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
    Berger F; Marce M; Delaloge S; Hardy-Bessard AC; Bachelot T; Bièche I; Pradines A; De La Motte Rouge T; Canon JL; André F; Arnould L; Clatot F; Lemonnier J; Marques S; Bidard FC;
    BMJ Open; 2022 Mar; 12(3):e055821. PubMed ID: 35241469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
    Fribbens C; O'Leary B; Kilburn L; Hrebien S; Garcia-Murillas I; Beaney M; Cristofanilli M; Andre F; Loi S; Loibl S; Jiang J; Bartlett CH; Koehler M; Dowsett M; Bliss JM; Johnston SR; Turner NC
    J Clin Oncol; 2016 Sep; 34(25):2961-8. PubMed ID: 27269946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
    Cani AK; Dolce EM; Darga EP; Hu K; Liu CJ; Pierce J; Bradbury K; Kilgour E; Aung K; Schiavon G; Carroll D; Carr TH; Klinowska T; Lindemann J; Marshall G; Rowlands V; Harrington EA; Barrett JC; Sathiyayogan N; Morrow C; Sero V; Armstrong AC; Baird R; Hamilton E; Im SA; Jhaveri K; Patel MR; Dive C; Tomlins SA; Udager AM; Hayes DF; Paoletti C
    Mol Oncol; 2022 May; 16(10):1969-1985. PubMed ID: 34866317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients.
    Babayan A; Hannemann J; Spötter J; Müller V; Pantel K; Joosse SA
    PLoS One; 2013; 8(9):e75038. PubMed ID: 24058649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
    Dubash TD; Bardia A; Chirn B; Reeves BA; LiCausi JA; Burr R; Wittner BS; Rai S; Patel H; Bihani T; Arlt H; Bidard FC; Kaklamani VG; Aftimos P; Cortés J; Scartoni S; Fiascarelli A; Binaschi M; Habboubi N; Iafrate AJ; Toner M; Haber DA; Maheswaran S
    Breast Cancer Res Treat; 2023 Aug; 201(1):43-56. PubMed ID: 37318638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.
    Chu D; Paoletti C; Gersch C; VanDenBerg DA; Zabransky DJ; Cochran RL; Wong HY; Toro PV; Cidado J; Croessmann S; Erlanger B; Cravero K; Kyker-Snowman K; Button B; Parsons HA; Dalton WB; Gillani R; Medford A; Aung K; Tokudome N; Chinnaiyan AM; Schott A; Robinson D; Jacks KS; Lauring J; Hurley PJ; Hayes DF; Rae JM; Park BH
    Clin Cancer Res; 2016 Feb; 22(4):993-9. PubMed ID: 26261103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
    Mu Z; Benali-Furet N; Uzan G; Znaty A; Ye Z; Paolillo C; Wang C; Austin L; Rossi G; Fortina P; Yang H; Cristofanilli M
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27706044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer.
    Kwan TT; Bardia A; Spring LM; Giobbie-Hurder A; Kalinich M; Dubash T; Sundaresan T; Hong X; LiCausi JA; Ho U; Silva EJ; Wittner BS; Sequist LV; Kapur R; Miyamoto DT; Toner M; Haber DA; Maheswaran S
    Cancer Discov; 2018 Oct; 8(10):1286-1299. PubMed ID: 30104333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.
    Yanagawa T; Kagara N; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2017 Jun; 163(2):231-240. PubMed ID: 28283903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot Study.
    Li X; Lu J; Zhang L; Luo Y; Zhao Z; Li M
    Transl Oncol; 2020 Feb; 13(2):321-328. PubMed ID: 31877464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
    Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
    Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
    Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
    Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts.
    Shaw JA; Guttery DS; Hills A; Fernandez-Garcia D; Page K; Rosales BM; Goddard KS; Hastings RK; Luo J; Ogle O; Woodley L; Ali S; Stebbing J; Coombes RC
    Clin Cancer Res; 2017 Jan; 23(1):88-96. PubMed ID: 27334837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
    Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
    Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical relevance of ESR1 circulating mutations detection in hormone receptor positive metastatic breast cancer].
    Clatot F; Perdrix A; Sefrioui D; Sarafan-Vasseur N; Di Fiore F
    Bull Cancer; 2018 Jan; 105(1):46-54. PubMed ID: 29032804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Super-ARMS: A new method for plasma ESR1 mutation detection.
    Chen Y; Zhao X; Wang L; Wu F; Zhang X; Wu H; Feng C; Liu M; Zhang Y; Zhang S
    Clin Chim Acta; 2021 Sep; 520():23-28. PubMed ID: 34048732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors.
    Leal MF; Haynes BP; Schuster E; Yeo B; Afentakis M; Zabaglo L; Martins V; Buus R; Dodson A; Cheang MCU; Smith IE; Martin LA; Dowsett M
    Clin Cancer Res; 2019 Dec; 25(24):7485-7496. PubMed ID: 31548345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.
    Paoletti C; Cani AK; Larios JM; Hovelson DH; Aung K; Darga EP; Cannell EM; Baratta PJ; Liu CJ; Chu D; Yazdani M; Blevins AR; Sero V; Tokudome N; Thomas DG; Gersch C; Schott AF; Wu YM; Lonigro R; Robinson DR; Chinnaiyan AM; Bischoff FZ; Johnson MD; Park BH; Hayes DF; Rae JM; Tomlins SA
    Cancer Res; 2018 Feb; 78(4):1110-1122. PubMed ID: 29233927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.